Plumbagin ameliorates CCl4-induced hepatic fibrosis in rats via the epidermal growth factor receptor signaling pathway

Evidence-based Complementary and Alternative Medicine

Volumn 2015, Issue , 2015, Pages

  Chen, Si ^a   Chen, Yi ^b   Chen, Bi ^c   Cai, Yi Jing ^b   Zou, Zhuo Lin ^b   Wang, Jin Guo ^c   Lin, Zhuo ^b   Wang, Xiao Dong ^b   Fu, Li Yun ^a   Hu, Yao Ren ^a   Chen, Yong Ping ^b   Chen, Da Zhi ^d  

^a NINGBO NO 2 HOSPITAL   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; ALANINE AMINOTRANSFERASE; ALPHA SMOOTH MUSCLE ACTIN; ASPARTATE AMINOTRANSFERASE; CARBON TETRACHLORIDE; COLLAGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; MESSENGER RNA; PLUMBAGIN; STAT3 PROTEIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CELL ACTIVATION; CELL INFILTRATION; COLLAGEN FIBER; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; HISTOPATHOLOGY; INFLAMMATORY CELL; LIVER FIBROSIS; LIVER INJURY; LIVER NECROSIS; MALE; MTT ASSAY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; RAT; SIGNAL TRANSDUCTION; STELLATE CELL;

EID: 84946202841     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2015/645727     Document Type: Article

References (54)

1. S. L. Friedman, "Mechanisms of Hepatic Fibrogenesis, " Gastroenterology, vol. 134, no. 6, pp. 1655-1669, 2008.
2. J. Rosenbloom, S. V. Castro, and S. A. Jimenez, "Narrative review: fibrotic diseases: cellular and molecular mechanisms and novel therapies, " Annals of Internal Medicine, vol. 152, no. 3, pp. 159-166, 2010.
3. J. Trebicka, M. Hennenberg, M. Odenthal et al., "Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells, " Journal of Hepatology, vol. 53, no. 4, pp. 702-712, 2010.
4. D. Y. Zhang and S. L. Friedman, "Fibrosis-dependent mechanisms of hepatocarcinogenesis, " Hepatology, vol. 56, no. 2, pp. 769-775, 2012.
5. V. J. Desmet and T. Roskams, "Cirrhosis reversal: a duelbetween dogma andmyth, " Journal of Hepatology, vol. 40, no. 5, pp. 860-867, 2004.
6. I. R. Wanless, E. Nakashima, and M. Sherman, "Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis, " Archives of Pathology and Laboratory Medicine, vol. 124, no. 11, pp. 1599-1607, 2000.
7. W.-C. Zhou, Q.-B. Zhang, and L. Qiao, "Pathogenesis of liver cirrhosis, "World Journal of Gastroenterology, vol. 20, no. 23, pp. 7312-7324, 2014.
8. J.-J. Zhang, X.-K. Meng, C. Dong et al., "Development of a new animal model of liver cirrhosis in swine, " European Surgical Research, vol. 42, no. 1, pp. 35-39, 2008.
9. H. C. Karantonis, G. Gribilas, I. Stamoulis et al., "Plateletactivating factor involvement in thioacetamide-induced experimental liver fibrosis and cirrhosis, " Digestive Diseases and Sciences, vol. 55, no. 2, pp. 276-284, 2010.
10. M.-F. Lee, M.-L. Liu, A.-C. Cheng et al., "Pterostilbene inhibits dimethylnitrosamine-induced liver fibrosis in rats, " Food Chemistry, vol. 138, no. 2-3, pp. 802-807, 2013.
11. J.-Y. Wang, J.-S. Guo, H. Li, S.-L. Liu, and M. A. Zern, "Inhibitory effect of glycyrrhizin onNF-kappaB binding activity in CCl(4-) plus ethanol-induced liver cirrhosis in rats, " Liver, vol. 18, no. 3, pp. 180-185, 1998.
12. S. S. Koca, I. H. Bahcecioglu, O. K. Poyrazoglu, I. H. Ozercan, K. Sahin, and B. Ustundag, "The treatment with antibody of TNF-α reduces the inflammation, necrosis and fibrosis in the nonalcoholic steatohepatitis induced by methionine- and cholinedeficient diet, " Inflammation, vol. 31, no. 2, pp. 91-98, 2008.
13. K. Kawaguchi, I. Sakaida, M. Tsuchiya, K. Omori, T. Takami, and K. Okita, "Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet, " Biochemical and Biophysical Research Communications, vol. 315, no. 1, pp. 187-195, 2004.
14. P. Ibanez, N. Solis, M. Pizarro et al., "Effect of losartan on early liver fibrosis development in a rat model of nonalcoholic steatohepatitis, " Journal ofGastroenterology andHepatology, vol. 22, no. 6, pp. 846-851, 2007.
15. T. C. H. Tan, D. H. G. Crawford, L. A. Jaskowski et al., "Excess iron modulates endoplasmic reticulum stress-associated pathways in a mouse model of alcohol and high-fat diet-induced liver injury, " Laboratory Investigation, vol. 93, no. 12, pp. 1295-1312, 2013.
16. J. Liang, B. Zhang, R.-W. Shen et al., "Preventive effect of halofuginone on concanavalin A-induced liver fibrosis, " PLoS ONE, vol. 8, no. 12, Article IDe82232, 2013.
17. C.-S. Wu, X.-X. Piao, D.-M. Piao, Y.-R. Jin, and C.-H. Li, "Treatment of pig serum-induced rat liver fibrosis with Boschniakia rossica, oxymatrine and interferon-α, " World Journal of Gastroenterology, vol. 11, no. 1, pp. 122-126, 2005.
18. L. Yang, J. Kwon, Y. Popov et al., "Vascular endothelial growth factor promotes fibrosis resolution and repair in mice, " Gastroenterology, vol. 146, no. 5, pp. 1339-1350. e1, 2014.
19. K.-L. Yang, K.-C. Hung, W.-T. Chang, and E. I. C. Li, "Establishment of an early liver fibrosismodel by the hydrodynamicsbased transfer of TGF-α1 gene, " Comparative Hepatology, vol. 6, article 9, 2007.
20. B. C. Fuchs, Y. Hoshida, T. Fujii et al., "Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma, " Hepatology, vol. 59, no. 4, pp. 1577-1590, 2014.
21. R. Samarakoon, A. D. Dobberfuhl, C. Cooley et al., "Induction of renal fibrotic genes by TGF-α1 requires EGFR activation, p53 and reactive oxygen species, " Cellular Signalling, vol. 25, no. 11, pp. 2198-2209, 2013.
22. J. Chen, J.-K. Chen, K. Nagai et al., "EGFR signaling promotes TGFα-dependent renal fibrosis, " Journal of theAmerican Society of Nephrology, vol. 23, no. 2, pp. 215-224, 2012.
23. S.-C. Chen, J.-Y. Guh, C.-C. Hwang et al., "Advanced glycation end-products activate extracellular signal-regulated kinase via the oxidative stress-EGF receptor pathway in renal fibroblasts, " Journal of Cellular Biochemistry, vol. 109, no. 1, pp. 38-48, 2010.
24. F. Zeng, A. B. Singh, and R. C. Harris, "The role of the EGF family of ligands and receptors in renal development, physiology and pathophysiology, " Experimental Cell Research, vol. 315, no. 4, pp. 602-610, 2009.
25. A. L. Means, K. C. Ray, A. B. Singh et al., "Overexpression of Heparin-binding EGF-like growth factor in mouse pancreas results in fibrosis and epithelial metaplasia, " Gastroenterology, vol. 124, no. 4, pp. 1020-1036, 2003.
26. B. Cheng, X. Fu, T. Sun, X. Sun, and Z. Sheng, "Expression of epidermal growth factor receptor and related phosphorylation proteins in hypertrophic scars and normal skin, " Chinese Medical Journal, vol. 115, no. 10, pp. 1525-1528, 2002.
27. N. Liu, J.-K. Guo, M. Pang et al., "Genetic or pharmacologic blockade of EGFR inhibits renal fibrosis, " Journal of the American Society of Nephrology, vol. 23, no. 5, pp. 854-867, 2012.
28. T.-P. Xu, H. Shen, L.-X. Liu, and Y.-Q. Shu, "Plumbagin from plumbago zeylanica l induces apoptosis in human non-small cell lung cancer cell lines through NF- κB inactivation, " Asian Pacific Journal of Cancer Prevention, vol. 14, no. 4, pp. 2325-2331, 2013.
29. R. Checker, D. Sharma, S. K. Sandur, S. Khanam, and T. B. Poduval, "Anti-inflammatory effects of plumbagin are mediated by inhibition of NF-kappaB activation in lymphocytes, " International Immunopharmacology, vol. 9, no. 7-8, pp. 949-958, 2009.
30. S. Sinha, K. Pal, A. Elkhanany et al., "Plumbagin inhibits tumorigenesis and angiogenesis of ovarian cancer cells in vivo, " International Journal of Cancer, vol. 132, no. 5, pp. 1201-1212, 2013.
31. R. Checker, R. S. Patwardhan, D. Sharma et al., "Plumbagin, a vitamin K3 analogue, abrogates lipopolysaccharide-induced oxidative stress, inflammation and endotoxic shock via NFkappaB suppression, " Inflammation, vol. 37, no. 2, pp. 542-554, 2014.
32. Y. Jia, J. Jing, Y. Bai et al., "Amelioration of experimental autoimmune encephalomyelitis by plumbagin through downregulation of JAK-STAT and NF-κB signaling pathways, " PLoS ONE, vol. 6, no. 10, Article IDe27006, 2011.
33. Y. Jiang, C. Wang, Y.-Y. Li et al., "Mistletoe alkaloid fractions alleviates carbon tetrachloride-induced liver fibrosis through inhibition of hepatic stellate cell activation via TGF-α/smad interference, " Journal of Ethnopharmacology, vol. 158, pp. 230-238, 2014.
34. M. Chevallier, S. Guerret, P. Chossegros, F. Gerard, and J. Grimaud, "A histological semiquantitative scoring system for evaluation of hepatic fibrosis in needle liver biopsy specimens: comparison with morphometric studies, " Hepatology, vol. 20, no. 2, pp. 349-355, 1994.
35. L.-P. Wang, J.-Z. Dong, L.-J. Xiong et al., "BMP-7 attenuates liver fibrosis via regulation of epidermal growth factor receptor, " International Journal of Clinical and Experimental Pathology, vol. 7, no. 7, pp. 3537-3547, 2014.
36. D. Schuppan and N. H. Afdhal, "Liver cirrhosis, "TheLancet, vol. 371, no. 9615, pp. 838-851, 2008.
37. F. J. Eng and S. L. Friedman, "Fibrogenesis. I. New insights into hepatic stellate cell activation: the simple becomes complex, " The American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 279, no. 1, pp. G7-G11, 2000.
38. A. Anan, E. S. Baskin-Bey, S. F. Bronk, N. W. Werneburg, V. H. Shah, and G. J. Gores, "Proteasome inhibition induces hepatic stellate cell apoptosis, " Hepatology, vol. 43, no. 2, pp. 335-344, 2006.
39. P. Zhai, J. Galeotti, J. Liu et al., "An angiotensin II type receptor mutant lacking epidermal growth factor receptor transactivation does not induce angiotensin II-mediated cardiac hypertrophy, " Circulation Research, vol. 99, no. 5, pp. 528-536, 2006.
40. L.-J. Yu, M.-L. Wu, H. Li et al., "Inhibition of STAT3 expression and signaling in resveratrol-differentiated medulloblastoma cells, " Neoplasia, vol. 10, no. 7, pp. 736-744, 2008.
41. M. Cichocki, H. Szaefer, V. Krajka-Kuzniak, and W. Baer- Dubowska, "The effect of resveratrol and its methylthioderivatives on EGFR and Stat3 activation in human HaCaT and A431 cells, " Molecular and Cellular Biochemistry, vol. 396, no. 1-2, pp. 221-228, 2014.
42. M.-Y. Xu, J.-J. Hu, J. Shen et al., "Stat3 signaling activation crosslinking of TGF-α1 in hepatic stellate cell exacerbates liver injury and fibrosis, " Biochimica et Biophysica Acta: Molecular Basis of Disease, vol. 1842, no. 11, pp. 2237-2245, 2014.
43. R. L. Carpenter and H.-W. Lo, "STAT3 target genes relevant to human cancers, " Cancers, vol. 6, no. 2, pp. 897-925, 2014.
44. A. Sorkin and L. K. Goh, "Endocytosis and intracellular trafficking of ErbBs, " Experimental Cell Research, vol. 314, no. 17, pp. 3093-3106, 2008.
45. S. Kiso, S. Kawata, S. Tamura et al., "Expression of heparinbinding epidermal growth factor-like growth factor in the hepatocytes of fibrotic rat liver during hepatocarcinogenesis, " Journal of Gastroenterology and Hepatology, vol. 14, no. 12, pp. 1203-1209, 1999.
46. D. Zhang, J. Zhang, X. Jiang et al., "Heparin-binding epidermal growth factor-like growth factor: a hepatic stellate cell proliferation inducer via ErbB receptors, " Journal of Gastroenterology and Hepatology, vol. 29, no. 3, pp. 623-632, 2014.
47. G. Huang, G. E. Besner, and D. R. Brigstock, "Heparinbinding epidermal growth factor-like growth factor suppresses experimental liver fibrosis in mice, " Laboratory Investigation, vol. 92, no. 5, pp. 703-712, 2012.
48. T. Takemura, Y. Yoshida, S. Kiso et al., "Conditional loss of heparin-binding EGF-like growth factor results in enhanced liver fibrosis after bile duct ligation in mice, " Biochemical and Biophysical Research Communications, vol. 437, no. 2, pp. 185-191, 2013.
49. D. Raghu and D. Karunagaran, "Plumbagin downregulates wnt signaling independent of p53 in human colorectal cancer cells, " Journal of Natural Products, vol. 77, no. 5, pp. 1130-1134, 2014.
50. R. Yong, X.-M. Chen, S. Shen et al., "Plumbagin ameliorates diabetic nephropathy via interruption of pathways that include NOX4 signalling, " PLoS ONE, vol. 8, no. 8, Article ID e73428, 2013.
51. Y. F. Wei, Molercular Mechanisms of Effect of Plumbagin on HumanHepatic Satellite Cells, GuangxiMedicalUniversity, 2011.
52. S. Sagar, L. Esau, B. Moosa, N. M. Khashab, V. B. Bajic, and M. Kaur, "Cytotoxicity and apoptosis induced by a plumbagin derivative in estrogen positiveMCF-7 breast cancer cells, " Anti- Cancer Agents inMedicinal Chemistry, vol. 14, no. 1, pp. 170-180, 2014.
53. K.-H. Xu and D.-P. Lu, "Plumbagin induces ROS-mediated apoptosis in human promyelocytic leukemia cells in vivo, " Leukemia Research, vol. 34, no. 5, pp. 658-665, 2010.
54. R. Parimala and P. Sachdanandam, "Effect of Plumbagin on some glucose metabolising enzymes studied in rats in experimental hepatoma, " Molecular and Cellular Biochemistry, vol. 125, no. 1, pp. 59-63, 1993.